• Explore /
  • Poster
  • / A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC).

A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

Pier VItale Nuzzo

Pier VItale Nuzzo

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY

Pier VItale Nuzzo , Caroline Fidalgo Ribeiro , Silvia Rodrigues , Escarleth Fernandez , Ana M. Molina , Jones Nauseef , Cora N. Sternberg , Scott T. Tagawa , Massimo Loda , David M. Nanus

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05743621

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS248)

DOI

10.1200/JCO.2024.42.4_suppl.TPS248

Abstract #

TPS248

Poster Bd #

Q9

Abstract Disclosures

Similar Posters

First Author: Evan Y. Yu

First Author: Mariona Calvo

First Author: David R Wise

Poster

2022 ASCO Genitourinary Cancers Symposium

Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).

Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).

First Author: Susan F. Slovin